Celea Therapeutics

Just days after completing our $180M financing, we've reached another defining milestone. The first patient has been dosed in SURPASS-IPF, the first industry-sponsored head-to-head Ph3 trial in #idiopathicpulmonaryfibrosis. SURPASS-IPF is designed to evaluate deupirfenidone against an approved antifibrotic & generate the evidence needed to meaningfully reshape how #IPF is treated. Read more: bit.ly/3SOjSdI

A new chapter begins for Celea Therapeutics. We're proud to announce a $180 million financing from a distinguished syndicate of leading healthcare investors to advance deupirfenidone. The financing enables the planned initiation of SURPASS-IPF, the first-ever industry-sponsored head-to-head Phase 3 trial in idiopathic pulmonary fibrosis (IPF). Thank you to our founder @PureTechH, investors, investigators, clinical trial participants, and everyone who helped make this milestone possible. We're just getting started. Read more: bit.ly/4ayytQn